Loading page…

Report overview

The report highlights the company's 2023 progress in reducing carbon emission intensity by 68% and energy intensity by 58% from 2020. It also reports the first disclosure of material Scope 3 data, completing the company's Scope 1-3 emissions inventory. In healthcare access, over 60,000 patients received the company's novel cancer medicines commercially, while its medicines marketed in China remained included in the NRDL.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 1 April 2024
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Water consumption
Waste
Employees
Women on the board
Women in management
Workplace fatalities
Net zero target

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services